Celldex Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $34.5500
- Today's High:
- $36.5200
- Open Price:
- $35.3400
- 52W Low:
- $19.85
- 52W High:
- $46.8
- Prev. Close:
- $35.3500
- Volume:
- 376722
Company Statistics
- Market Cap.:
- $1.617 billion
- Book Value:
- 7.81
- Revenue TTM:
- $0.001 billion
- Operating Margin TTM:
- -11097%
- Gross Profit TTM:
- $-0.049 billion
- Gross Profit TTM:
- $-0.049 billion
- Profit Margin:
- 0%
- Return on Assets TTM:
- -18.8%
- Return on Equity TTM:
- -36.4%
Company Profile
Celldex Therapeutics Inc had its IPO on 1990-03-26 under the ticker symbol CLDX.
The company operates in the LIFE SCIENCES sector and IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry. Celldex Therapeutics Inc has a staff strength of 0 employees.
Stock update
Shares of Celldex Therapeutics Inc opened at $35.34 at the start of the last trading session i.e. 2022-11-02.
The stocks traded within a range of $34.55 - $36.52, and closed at $34.58.
This is a -2.18% slip from the previous day's closing price.
A total volume of 376,722 shares were traded at the close of the day’s session.
In the last one week, shares of Celldex Therapeutics Inc have increased by +1.71%.
Celldex Therapeutics Inc's Key Ratios
Celldex Therapeutics Inc has a market cap of $1.617 billion, indicating a price to book ratio of 4.544 and a price to sales ratio of 1965.24.
In the last 12-months Celldex Therapeutics Inc’s revenue was $0.001 billion with a gross profit of $-0.049 billion and an EBITDA of $-0.088 billion. The EBITDA ratio measures Celldex Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Celldex Therapeutics Inc’s operating margin was -11097% while its return on assets stood at -18.8% with a return of equity of -36.4%.
In Q2, Celldex Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 95.3%.
Celldex Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- -
- Trailing PE
- -
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.725 per share while it has a forward price to earnings multiple of - and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Celldex Therapeutics Inc’s profitability.
Celldex Therapeutics Inc stock is trading at a EV to sales ratio of 1587.13 and a EV to EBITDA ratio of -14.8. Its price to sales ratio in the trailing 12-months stood at 1965.24.
Celldex Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $0.000 billion
- Total Liabilities
- $0.000 billion
- Operating Cash Flow
- $0.000 billion
- Capital Expenditure
- $0.000 billion
- Dividend Payout Ratio
- 0%
Celldex Therapeutics Inc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.
Celldex Therapeutics Inc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.
Celldex Therapeutics Inc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.
In 1970, Celldex Therapeutics Inc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.
Comparatively, Celldex Therapeutics Inc paid $0 billion in dividends in 1970.
Other key metrics
- Current Trading Price
- $34.58
- 52-Week High
- $46.8
- 52-Week Low
- $19.85
- Analyst Target Price
- $65.17
Celldex Therapeutics Inc stock is currently trading at $34.58 per share. It touched a 52-week high of $46.8 and a 52-week low of $46.8. Analysts tracking the stock have a 12-month average target price of $65.17.
Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 0% are held by institutions.
Frequently Asked Questions About Celldex Therapeutics Inc
Similar Industry Stocks (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)
Most Active
Top Gainers
Top Losers
About
Celldex Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development of therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. The company is headquartered in Hampton, New Jersey.